CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on
progression free survival (PFS) defined as the time from start of treatment until the
objective observation of progressive disease (PD) or death from any course in patients with
chemotherapy-refractory metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cytavis Biopharma GmbH
Collaborators:
Charite University, Berlin, Germany ClinAssess GmbH Medical University Innsbruck